ATN-022
Claudin 18.2 Expressing Tumors
Phase IIActive
Key Facts
About Antennova
Antennova is a private, pre-revenue biotech advancing a clinical-stage pipeline of four novel oncology assets targeting key immune pathways. Its portfolio includes an ADC, a small molecule inhibitor, and bispecific/monoclonal antibodies, all designed with differentiation to overcome limitations of existing therapies, such as targeting low antigen expressors or reversing checkpoint inhibitor resistance. The company leverages deep immuno-oncology expertise to create a synergistic portfolio aimed at combination therapies for a broad range of solid tumors and hematologic malignancies.
View full company profile